Cargando…

Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles

Chlamydia trachomatis is a bacterial sexually transmitted infection affecting millions of people worldwide. Previous vaccination attempts have employed the recombinant major outer membrane protein (MOMP) of C. trachomatis nonetheless, with limited success, perhaps, due to stability, degradation, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Cambridge, Chino D, Singh, Shree R, Waffo, Alain B, Fairley, Stacie J, Dennis, Vida A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656902/
https://www.ncbi.nlm.nih.gov/pubmed/23690681
http://dx.doi.org/10.2147/IJN.S42723
_version_ 1782270074345750528
author Cambridge, Chino D
Singh, Shree R
Waffo, Alain B
Fairley, Stacie J
Dennis, Vida A
author_facet Cambridge, Chino D
Singh, Shree R
Waffo, Alain B
Fairley, Stacie J
Dennis, Vida A
author_sort Cambridge, Chino D
collection PubMed
description Chlamydia trachomatis is a bacterial sexually transmitted infection affecting millions of people worldwide. Previous vaccination attempts have employed the recombinant major outer membrane protein (MOMP) of C. trachomatis nonetheless, with limited success, perhaps, due to stability, degradation, and delivery issues. In this study we cloned C. trachomatis recombinant MOMP DNA (DMOMP) and encapsulated it in chitosan nanoparticles (DMCNP) using the complex coacervation technique. Physiochemical characterizations of DMCNP included transmission and scanning electron microcopy, Fourier transform infrared and ultraviolet-visible spectroscopy, and zeta potential. Encapsulated DMOMP was 167–250 nm, with a uniform spherical shape and homogenous morphology, and an encapsulation efficiency > 90%. A slow release pattern of encapsulated DMOMP, especially in acidic solution, was observed over 7 days. The zeta potential of DMCNP was ~8.80 mV, which indicated that it was highly stable. Toxicity studies of DMCNP (25–400 μg/mL) to Cos-7 cells using the MTT assay revealed minimal toxicity over 24–72 hours with >90% viable cells. Ultra-violet visible (UV-vis) spectra indicated encapsulated DMOMP protection by chitosan, whereas agarose gel electrophoresis verified its protection from enzymatic degradation. Expression of MOMP protein in DMCNP-transfected Cos-7 cells was demonstrated via Western blotting and immunofluorescence microscopy. Significantly, intramuscular injection of BALB/c mice with DMCNP confirmed the delivery of encapsulated DMOMP, and expression of the MOMP gene transcript in thigh muscles and spleens. Our data show that encapsulation of DMOMP in biodegradable chitosan nanoparticles imparts stability and protection from enzymatic digestion, and enhances delivery and expression of DMOMP in vitro and in mice. Further investigations of the nanoencapsulated DMCNP vaccine formulation against C. trachomatis in mice are warranted.
format Online
Article
Text
id pubmed-3656902
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-36569022013-05-20 Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles Cambridge, Chino D Singh, Shree R Waffo, Alain B Fairley, Stacie J Dennis, Vida A Int J Nanomedicine Original Research Chlamydia trachomatis is a bacterial sexually transmitted infection affecting millions of people worldwide. Previous vaccination attempts have employed the recombinant major outer membrane protein (MOMP) of C. trachomatis nonetheless, with limited success, perhaps, due to stability, degradation, and delivery issues. In this study we cloned C. trachomatis recombinant MOMP DNA (DMOMP) and encapsulated it in chitosan nanoparticles (DMCNP) using the complex coacervation technique. Physiochemical characterizations of DMCNP included transmission and scanning electron microcopy, Fourier transform infrared and ultraviolet-visible spectroscopy, and zeta potential. Encapsulated DMOMP was 167–250 nm, with a uniform spherical shape and homogenous morphology, and an encapsulation efficiency > 90%. A slow release pattern of encapsulated DMOMP, especially in acidic solution, was observed over 7 days. The zeta potential of DMCNP was ~8.80 mV, which indicated that it was highly stable. Toxicity studies of DMCNP (25–400 μg/mL) to Cos-7 cells using the MTT assay revealed minimal toxicity over 24–72 hours with >90% viable cells. Ultra-violet visible (UV-vis) spectra indicated encapsulated DMOMP protection by chitosan, whereas agarose gel electrophoresis verified its protection from enzymatic degradation. Expression of MOMP protein in DMCNP-transfected Cos-7 cells was demonstrated via Western blotting and immunofluorescence microscopy. Significantly, intramuscular injection of BALB/c mice with DMCNP confirmed the delivery of encapsulated DMOMP, and expression of the MOMP gene transcript in thigh muscles and spleens. Our data show that encapsulation of DMOMP in biodegradable chitosan nanoparticles imparts stability and protection from enzymatic digestion, and enhances delivery and expression of DMOMP in vitro and in mice. Further investigations of the nanoencapsulated DMCNP vaccine formulation against C. trachomatis in mice are warranted. Dove Medical Press 2013 2013-05-10 /pmc/articles/PMC3656902/ /pubmed/23690681 http://dx.doi.org/10.2147/IJN.S42723 Text en © 2013 Cambridge et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Cambridge, Chino D
Singh, Shree R
Waffo, Alain B
Fairley, Stacie J
Dennis, Vida A
Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles
title Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles
title_full Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles
title_fullStr Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles
title_full_unstemmed Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles
title_short Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles
title_sort formulation, characterization, and expression of a recombinant momp chlamydia trachomatis dna vaccine encapsulated in chitosan nanoparticles
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656902/
https://www.ncbi.nlm.nih.gov/pubmed/23690681
http://dx.doi.org/10.2147/IJN.S42723
work_keys_str_mv AT cambridgechinod formulationcharacterizationandexpressionofarecombinantmompchlamydiatrachomatisdnavaccineencapsulatedinchitosannanoparticles
AT singhshreer formulationcharacterizationandexpressionofarecombinantmompchlamydiatrachomatisdnavaccineencapsulatedinchitosannanoparticles
AT waffoalainb formulationcharacterizationandexpressionofarecombinantmompchlamydiatrachomatisdnavaccineencapsulatedinchitosannanoparticles
AT fairleystaciej formulationcharacterizationandexpressionofarecombinantmompchlamydiatrachomatisdnavaccineencapsulatedinchitosannanoparticles
AT dennisvidaa formulationcharacterizationandexpressionofarecombinantmompchlamydiatrachomatisdnavaccineencapsulatedinchitosannanoparticles